Active donor t cell stat6
OwnerMirac Nedim Ince, David Elliottinventors
Life of this patent
Estimating the term…
Abstract
Provided herein is the use of donor T cells that express a continuously active form of STAT6, e.g., before or during BMT/HCT or after BMT/HCT, the use of autologous T cells genetically engineered to express a continuously active form of STAT6 to prevent, inhibit or treat immune diseases including autoimmune diseases and the use of T cells genetically engineered to express a continuously active form of STAT6 to enhance an immune response to a vaccine.
Claims16
A method to enhance the efficacy of a bone marrow transplant (BMT) in a mammal comprising administering to a mammal in need thereof an amount of a population of hematopoietic stem cells (HSCs) and an amount of isolated T cells that express constitutively active STAT6.
A method to prevent, inhibit or treat an autoimmune disease or to enhance memory cell generation in a mammal comprising administering to a mammal in need thereof an amount of isolated T cells that express constitutively active STAT6, a vector that expresses constitutively active STAT6 or isolated constitutively active STAT6.
A method to enhance the immune response to a pathogen in a mammal comprising administering to a mammal in need thereof an amount of isolated T cells that express constitutively active STAT6, a vector that expresses constitutively active STAT6 or isolated constitutively active STAT6 and an immunogen of the pathogen.
A population of isolated human T cells the genome of which comprises a nucleic acid sequence encoding a constitutively active form of human STAT6.
Dependencies are inferred from the claim text.